OBJECTIVE: The purpose of this study was to investigate possible differences in the primary in situ cellular immune response between patients with and without relapse of Stage IB cervical squamous cell carcinoma. METHOD: Paraffin-embedded tissue from 40 patients (20 with and 20 without relapse) was evaluated. Sections were immunostained for CD1a+, CD3+, CD4+, CD8+, CD20+, CD45RA+, CD45RO+, CD57+, CD68+ and GrB+ cells. Immune cell profile densities were estimated using stereology. RESULTS: We found significantly lower densities of CD3+, CD4+, CD8+ and CD57+ cells (both intra- and peritumoral) in tissue from patients who had relapse. Also densities of intratumoral CD1a+ cells and peritumoral CD20+, CD45RA+ and CD45RO+ cells were significantly lower among patients with relapse. CONCLUSION: This study demonstrates striking differences in the cellular immune response between patients with and without relapse within 5 years. The results are of potential value in adjuvant immunotherapy and prediction of prognosis.
OBJECTIVE: The purpose of this study was to investigate possible differences in the primary in situ cellular immune response between patients with and without relapse of Stage IB cervical squamous cell carcinoma. METHOD:Paraffin-embedded tissue from 40 patients (20 with and 20 without relapse) was evaluated. Sections were immunostained for CD1a+, CD3+, CD4+, CD8+, CD20+, CD45RA+, CD45RO+, CD57+, CD68+ and GrB+ cells. Immune cell profile densities were estimated using stereology. RESULTS: We found significantly lower densities of CD3+, CD4+, CD8+ and CD57+ cells (both intra- and peritumoral) in tissue from patients who had relapse. Also densities of intratumoral CD1a+ cells and peritumoral CD20+, CD45RA+ and CD45RO+ cells were significantly lower among patients with relapse. CONCLUSION: This study demonstrates striking differences in the cellular immune response between patients with and without relapse within 5 years. The results are of potential value in adjuvant immunotherapy and prediction of prognosis.
Authors: Richard Fristedt; David Borg; Charlotta Hedner; Jonna Berntsson; Björn Nodin; Jakob Eberhard; Patrick Micke; Karin Jirström Journal: J Gastrointest Oncol Date: 2016-12
Authors: Tullia C Bruno; Peggy J Ebner; Brandon L Moore; Olivia G Squalls; Katherine A Waugh; Evgeniy B Eruslanov; Sunil Singhal; John D Mitchell; Wilbur A Franklin; Daniel T Merrick; Martin D McCarter; Brent E Palmer; Jeffrey A Kern; Jill E Slansky Journal: Cancer Immunol Res Date: 2017-08-28 Impact factor: 11.151
Authors: Anthony R Cillo; Cornelius H L Kürten; Tracy Tabib; Zengbiao Qi; Sayali Onkar; Ting Wang; Angen Liu; Umamaheswar Duvvuri; Seungwon Kim; Ryan J Soose; Steffi Oesterreich; Wei Chen; Robert Lafyatis; Tullia C Bruno; Robert L Ferris; Dario A A Vignali Journal: Immunity Date: 2020-01-07 Impact factor: 31.745
Authors: Katy Milne; Martin Köbel; Steven E Kalloger; Rebecca O Barnes; Dongxia Gao; C Blake Gilks; Peter H Watson; Brad H Nelson Journal: PLoS One Date: 2009-07-29 Impact factor: 3.240